Patents by Inventor Pappachan E. Kolattukudy

Pappachan E. Kolattukudy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8999314
    Abstract: Disclosed herein are methods and compositions of treating a subject suffering from a wound. In exemplary examples, the method involves elevating MCPIP levels in a subject in need. Elevating MCPIP levels may involve direct administration (e.g. delivery of protein) or indirect administration (e.g. delivery vehicle capable of increasing expression of MCPIP).
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: April 7, 2015
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Pappachan E. Kolattukudy, Jianli Niu
  • Publication number: 20140341877
    Abstract: Disclosed herein are methods and compositions of treating a subject suffering from a wound. In exemplary examples, the method involves elevating MCPIP levels in a subject in need. Elevating MCPIP levels may involve direct administration (e.g. delivery of protein) or indirect administration (e.g. delivery vehicle capable of increasing expression of MCPIP).
    Type: Application
    Filed: April 21, 2014
    Publication date: November 20, 2014
    Applicant: University of Central Florida Research Foundation, Inc.
    Inventors: Pappachan E. Kolattukudy, Jianli Niu
  • Patent number: 8703703
    Abstract: Disclosed herein are methods and compositions of treating a subject suffering from a wound. In exemplary examples, the method involves elevating MCPIP levels in a subject in need. Elevating MCPIP levels may involve direct administration (e.g. delivery of protein) or indirect administration (e.g. delivery vehicle capable of increasing expression of MCPIP).
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 22, 2014
    Assignee: University of Central Flordia Research Foundation, Inc.
    Inventors: Pappachan E. Kolattukudy, Jianli Niu
  • Publication number: 20130295076
    Abstract: Disclosed herein are methods and compositions of treating a subject suffering from a wound. In exemplary examples, the method involves elevating MCPIP levels in a subject in need. Elevating MCPIP levels may involve direct administration (e.g. delivery of protein) or indirect administration (e.g. delivery vehicle capable of increasing expression of MCPIP).
    Type: Application
    Filed: March 14, 2013
    Publication date: November 7, 2013
    Applicant: University of Central Florida Research Foundation Inc.
    Inventors: Pappachan E. Kolattukudy, Jianli Niu
  • Patent number: 8551499
    Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: October 8, 2013
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajyoti Deb
  • Publication number: 20130040829
    Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.
    Type: Application
    Filed: August 13, 2012
    Publication date: February 14, 2013
    Applicant: University of Central Florida Research Foundation, Inc.
    Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajoti Deb
  • Patent number: 8241644
    Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: August 14, 2012
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajyoti Deb
  • Patent number: 8211446
    Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: July 3, 2012
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajyoti Deb
  • Patent number: 8039605
    Abstract: Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol hydrolase like polypeptides or polynucleotides encoding the same. The methods are useful in identifying agents active against TB infection.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: October 18, 2011
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Pappachan E. Kolattukudy, Chirajyoti Deb, Jaiyanth Daniel
  • Patent number: 7993658
    Abstract: Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol synthase like polypeptides or polynucleotides encoding the same. The methods are useful in identifying agents active against TB infection.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: August 9, 2011
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Vinod S. Dubey, Jaiyanth Daniel
  • Publication number: 20110190479
    Abstract: The application reports the discovery that mycobacterial triacylglycerol synthase (MTTGS) enzymes also have a wax synthase function. This bifunctional enzymatic activity, or ‘dual function,’ implies that the enzymes contain separate binding sites for diacylglycerol and acyl alcohol and a common binding site for acyl-coenzyme A. Embodiments of the invention relate to methods of selection and/or design of therapeutic compounds that will reduce any potentially toxic side effects of candidate drugs designed to inhibit the mycobacterial enzyme.
    Type: Application
    Filed: January 3, 2011
    Publication date: August 4, 2011
    Inventors: PAPPACHAN E. KOLATTUKUDY, TATIANA SIRAKOVA, VINOD S. DUBEY, JAIYANTH DANIEL
  • Publication number: 20110033915
    Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.
    Type: Application
    Filed: August 30, 2010
    Publication date: February 10, 2011
    Applicant: University of Central Florida Research Foundation, Inc.
    Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajyoti Deb
  • Publication number: 20110002981
    Abstract: Disclosed herein are methods and compositions of treating a patient at risk of experiencing sepsis induced cardiac dysfunction. In exemplary examples, the method involves elevating MCPIP levels in a patient in need. Elevating MCPIP levels may involve direct administration (e.g. delivery of protein) or indirect administration (e.g. delivery vehicle capable of increasing expression of MCPIP).
    Type: Application
    Filed: August 19, 2010
    Publication date: January 6, 2011
    Inventors: Pappachan E. Kolattukudy, Jianli Niu
  • Publication number: 20100021453
    Abstract: Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol synthase like polypeptides or polynucleotides encoding the same. The methods are useful in identifying agents active against TB infection.
    Type: Application
    Filed: August 24, 2009
    Publication date: January 28, 2010
    Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Vinod S. Dubey, Jaiyanth Daniel
  • Publication number: 20100008903
    Abstract: Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol hydrolase like polypeptides or polynucleotides encoding the same. The methods are useful in identifying agents active against TB infection.
    Type: Application
    Filed: August 25, 2009
    Publication date: January 14, 2010
    Inventors: Pappachan E. Kolattukudy, Chirajyoti Deb, Jaiyanth Daniel
  • Patent number: 7601357
    Abstract: Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol hydrolase like polypeptides or polynucleotides encoding the same. The methods are useful in identifying agents active against TB infection.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: October 13, 2009
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Pappachan E. Kolattukudy, Chirajyoti Deb, Jaiyanth Daniel
  • Patent number: 7579012
    Abstract: Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol synthase like polypeptides or polynucleotides encoding the same. The methods are useful in identifying agents active against TB infection.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: August 25, 2009
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Pappachan E. Kolattukudy, Tatiano Sirakova, Vinod S. Dubey, Jaiyanth Daniel
  • Patent number: 6562349
    Abstract: It has been discovered that a vaccine comprised of fimbrin, a filamentous protein derived from the bacterial surface appendages of non-typable Haemophilus influenzae is useful in studying, preventing or reducing the severity of, otitis media. The gene sequence of the DNA coding for fimbrin and the amino acid sequence of fimbrin have also been determined. Vectors containing DNA coding for fimbrin have also been developed, and transformants have been prepared which contain such vectors and which express such DNA and provide a source of pure fimbrin.
    Type: Grant
    Filed: November 29, 1999
    Date of Patent: May 13, 2003
    Assignee: The Ohio State University Research Foundation
    Inventors: Pappachan E. Kolattukudy, Lauren O. Bakaletz, Tatiana Sirakova
  • Patent number: 6030626
    Abstract: It has been discovered that a vaccine comprised of fimbrin, a filamentous protein derived from the bacterial surface appendages of non-typable Haemophilus influenzae is useful in studying, preventing or reducing the severity of, otitis media. The gene sequence of the DNA coding for fimbrin and the amino acid sequence of fimbrin have also been determined. Vectors containing DNA coding for fimbrin have also been developed, and transformants have been prepared which contain such vectors and which express such DNA and provide a source of pure fimbrin.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 29, 2000
    Assignee: Ohio State Research Foundation
    Inventors: Pappachan E. Kolattukudy, Lauren O. Bakaletz, Tatiana Sirakova
  • Patent number: 5766608
    Abstract: It has been discovered that a vaccine comprised of fimbrin, a filamentous protein derived from the bacterial surface appendages of non-typable Haemophilus influenzae is useful in studying, preventing or reducing the severity of, otitis media. The gene sequence of the DNA coding for fimbrin and the amino acid sequence of fimbrin have also been determined. Vectors containing DNA coding for fimbrin have also been developed, and transformants have been prepared which contain such vectors and which express such DNA and provide a source of pure fimbrin.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: June 16, 1998
    Assignee: The Ohio State Research Foundation
    Inventors: Pappachan E. Kolattukudy, Lauren O. Bakaletz, Tatiana Sirakova